Fiche publication
Date publication
mars 2026
Journal
Critical reviews in oncology/hematology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier
,
Dr EBERST Guillaume
Tous les auteurs :
Damon M, Clairet AL, Eberst G, Adotévi O
Lien Pubmed
Résumé
Therapeutic cancer vaccines aim to expand tumor-antigen-specific T lymphocytes to eliminate cancer cells selectively. Recent advances in identifying neoantigens arising from genomic mutations in tumor cells, along with progress in vaccine-platform engineering, particularly in messenger RNA technologies, have revitalized the clinical development of cancer vaccines. Promising data from clinical trials of adjuvant vaccination in early-stage disease demonstrate the interest of vaccination for preventing recurrence. In this review, we describe the immunological rationale of cancer vaccines in the early stages of cancer. We also discuss the rationale for neoadjuvant cancer vaccination in combination with cotherapy such as chemotherapy or immune checkpoint inhibitors (ICIs).
Mots clés
Cancer vaccine, adjuvant, early-stage cancer, neoadjuvant, non-personalized vaccine, personalized vaccine
Référence
Crit Rev Oncol Hematol. 2026 03 21;:105290
